Limits...
mRNA expression of somatostatin receptor subtypes SSTR-2, SSTR-3, and SSTR-5 and its significance in pancreatic cancer.

Shahbaz M, Ruliang F, Xu Z, Benjia L, Cong W, Zhaobin H, Jun N - World J Surg Oncol (2015)

Bottom Line: The aim of this study is to investigate the expressions of somatostatin receptor (SSTR), SSTR-2, SSTR-3, and SSTR-5, in pancreatic tissue and non-cancerous tissue and elucidate their clinical significance.SSTR-5 mRNA expression rates were 13.0% (14/108) and 18.5% (20/108).We propose that SSTR-2 plays an important role in clinical implications for patients with pancreatic cancer undergoing somatostatin or its analog therapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Hepatobiliary Surgery, Qilu Hospital, Shandong University, Wenhua west Road #44, Jinan, 250012, China. apexshahbaz@gmail.com.

ABSTRACT

Background: The aim of this study is to investigate the expressions of somatostatin receptor (SSTR), SSTR-2, SSTR-3, and SSTR-5, in pancreatic tissue and non-cancerous tissue and elucidate their clinical significance.

Methods: The expression of somatostatin receptor subtypes SSTR-2, SSTR-3, and SSTR-5 messenger RNA (mRNA) in 108 cases of cancer tissue and adjacent tissue in patients with pancreatic cancer was detected by reverse transcriptase polymerase chain reaction (RT-PCR). Expression of SSTR-2, SSTR-3, and SSTR-5 mRNA was evaluated after specimens were taken from selected patients who underwent surgical resection by Whipple's operation. We speculated the clinical significance of the expression of somatostatin receptor (SSTR) subtype genes SSTR-2, SSTR-3, and SSTR-5 in pancreatic tissue and non-cancerous tissue and further elucidated their clinical significance.

Results: The expression rates of SSTR-2 mRNA in cancer and adjacent tissue of 108 patients with pancreatic cancer were 81.5% (88/108) and 97.2% (105/108), respectively; SSTR-3 mRNA expression rates were 69.4% (75/108) and 55.6% (60/108). SSTR-5 mRNA expression rates were 13.0% (14/108) and 18.5% (20/108).

Conclusion: We propose that SSTR-2 plays an important role in clinical implications for patients with pancreatic cancer undergoing somatostatin or its analog therapy.

Show MeSH

Related in: MedlinePlus

Overall survival according toSSTR-2,SSTR-3,SSTR-5mRNA expression in pancreatic cancer patients. (a) Overall survival according to SSTR-2 mRNA expression in pancreatic cancer patients. (b) Overall survival according to SSTR-3 mRNA expression in pancreatic cancer patients. (c) Overall survival according to SSTR-5 mRNA expression in pancreatic cancer patients.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4328977&req=5

Fig1: Overall survival according toSSTR-2,SSTR-3,SSTR-5mRNA expression in pancreatic cancer patients. (a) Overall survival according to SSTR-2 mRNA expression in pancreatic cancer patients. (b) Overall survival according to SSTR-3 mRNA expression in pancreatic cancer patients. (c) Overall survival according to SSTR-5 mRNA expression in pancreatic cancer patients.

Mentions: Survival curves are shown in Figure 1a-c. Patients with positive SSTR-2 mRNA expression in carcinous tissue had a significantly better overall survival rate than those with negative expression (P < 0.05, the log-rank test, χ2 = 4.40). The difference of a patients’ survival rate between positive and negative SSTR-3 expression in carcinous tissue had no statistical significance (P > 0.05, the log-rank test, χ2 = 0.003), and the difference of a patients’ survival rate between positive and negative SSTR-5 expression in carcinous tissue also had no statistical significance (P > 0.05, the log-rank test, χ2 = 0.391).Figure 1


mRNA expression of somatostatin receptor subtypes SSTR-2, SSTR-3, and SSTR-5 and its significance in pancreatic cancer.

Shahbaz M, Ruliang F, Xu Z, Benjia L, Cong W, Zhaobin H, Jun N - World J Surg Oncol (2015)

Overall survival according toSSTR-2,SSTR-3,SSTR-5mRNA expression in pancreatic cancer patients. (a) Overall survival according to SSTR-2 mRNA expression in pancreatic cancer patients. (b) Overall survival according to SSTR-3 mRNA expression in pancreatic cancer patients. (c) Overall survival according to SSTR-5 mRNA expression in pancreatic cancer patients.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4328977&req=5

Fig1: Overall survival according toSSTR-2,SSTR-3,SSTR-5mRNA expression in pancreatic cancer patients. (a) Overall survival according to SSTR-2 mRNA expression in pancreatic cancer patients. (b) Overall survival according to SSTR-3 mRNA expression in pancreatic cancer patients. (c) Overall survival according to SSTR-5 mRNA expression in pancreatic cancer patients.
Mentions: Survival curves are shown in Figure 1a-c. Patients with positive SSTR-2 mRNA expression in carcinous tissue had a significantly better overall survival rate than those with negative expression (P < 0.05, the log-rank test, χ2 = 4.40). The difference of a patients’ survival rate between positive and negative SSTR-3 expression in carcinous tissue had no statistical significance (P > 0.05, the log-rank test, χ2 = 0.003), and the difference of a patients’ survival rate between positive and negative SSTR-5 expression in carcinous tissue also had no statistical significance (P > 0.05, the log-rank test, χ2 = 0.391).Figure 1

Bottom Line: The aim of this study is to investigate the expressions of somatostatin receptor (SSTR), SSTR-2, SSTR-3, and SSTR-5, in pancreatic tissue and non-cancerous tissue and elucidate their clinical significance.SSTR-5 mRNA expression rates were 13.0% (14/108) and 18.5% (20/108).We propose that SSTR-2 plays an important role in clinical implications for patients with pancreatic cancer undergoing somatostatin or its analog therapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Hepatobiliary Surgery, Qilu Hospital, Shandong University, Wenhua west Road #44, Jinan, 250012, China. apexshahbaz@gmail.com.

ABSTRACT

Background: The aim of this study is to investigate the expressions of somatostatin receptor (SSTR), SSTR-2, SSTR-3, and SSTR-5, in pancreatic tissue and non-cancerous tissue and elucidate their clinical significance.

Methods: The expression of somatostatin receptor subtypes SSTR-2, SSTR-3, and SSTR-5 messenger RNA (mRNA) in 108 cases of cancer tissue and adjacent tissue in patients with pancreatic cancer was detected by reverse transcriptase polymerase chain reaction (RT-PCR). Expression of SSTR-2, SSTR-3, and SSTR-5 mRNA was evaluated after specimens were taken from selected patients who underwent surgical resection by Whipple's operation. We speculated the clinical significance of the expression of somatostatin receptor (SSTR) subtype genes SSTR-2, SSTR-3, and SSTR-5 in pancreatic tissue and non-cancerous tissue and further elucidated their clinical significance.

Results: The expression rates of SSTR-2 mRNA in cancer and adjacent tissue of 108 patients with pancreatic cancer were 81.5% (88/108) and 97.2% (105/108), respectively; SSTR-3 mRNA expression rates were 69.4% (75/108) and 55.6% (60/108). SSTR-5 mRNA expression rates were 13.0% (14/108) and 18.5% (20/108).

Conclusion: We propose that SSTR-2 plays an important role in clinical implications for patients with pancreatic cancer undergoing somatostatin or its analog therapy.

Show MeSH
Related in: MedlinePlus